 |
|
|
| |
Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study / ASTRAL 1, 2 and 3
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 131-17 San Francisco
Michael R. Charlton,1 Jacqueline G. O'Leary,2 Natalie H. Bzowej,3 Andrew J. Muir,4 Kevin M. Korenblat,5 Jonathan M. Fenkel,6 K. Rajender Reddy,7 Eric Lawitz,8 Thomas D. Schiano,9 Lewis W. Teperman,10
Robert J. Fontana,11 Eugene R. Schiff,12 Michael W. Fried,13 Brian Doehle,14 Di An,14 John McNally,14 Anu Osinusi,14 Diana M. Brainard,14 John G. McHutchison,14 Robert S. Brown,15 Michael P. Curry16
1Intermountain Medical Center, Murray, UT; 2Baylor Research Institute, Dallas, TX; 3Ochsner Medical Center, New Orleans, LA; 4Duke University, Durham, NC; 5Washington University School of Medicine in Saint Louis, MO; 6Thomas Jefferson University, Philadelphia, PA; 7University of Pennsylvania School of Medicine, Philadelphia, PA; 8Texas Liver Institute, San Antonio, TX;
9Mount Sinai Hospital, New York, NY; 10NYU School of Medicine, New York, NY; 11University of Michigan, Ann Arbor, MI; 12University of Miami, Coral Gables, FL; 13University of North Carolina at Chapel Hill School of Medicine, NC; 14Gilead Sciences, Inc., Foster City, CA; 15Columbia University Medical Center, New York-Presbyterian, New York, NY; 16Beth Israel Deaconess Medical Center, Boston, MA
-----------------------------------
Sofosbuvir + GS-5816: ASTRAL 1, 2, 3 and 4 at AASLD, just published
AASLD: A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Genotype 1, 2, 4, 5, 6 HCV-Infected Patients: Results of the ASTRAL-1 Study - (11/17/15)
AASLD: Sofosbuvir With Velpatasvir (GS-5816) in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15)
AASLD: Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients - (11/16/15)
AASLD: Sofosbuvir Plus Velpatasvir (GS-5816) Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15)
AASLD: Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - (11/16/15)
-------------------------------
Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study
Reported by Jules Levin
AASLD 2015 Nov 131-17 San Francisco
Michael R. Charlton,1 Jacqueline G. O'Leary,2 Natalie H. Bzowej,3 Andrew J. Muir,4 Kevin M. Korenblat,5 Jonathan M. Fenkel,6 K. Rajender Reddy,7 Eric Lawitz,8 Thomas D. Schiano,9 Lewis W. Teperman,10 Robert J. Fontana,11 Eugene R. Schiff,12 Michael W. Fried,13 Brian Doehle,14 Di An,14 John McNally,14 Anu Osinusi,14 Diana M. Brainard,14 John G. McHutchison,14 Robert S. Brown,15 Michael P. Curry16
1Intermountain Medical Center, Murray, UT; 2Baylor Research Institute, Dallas, TX; 3Ochsner Medical Center, New Orleans, LA; 4Duke University, Durham, NC; 5Washington University School of Medicine in Saint Louis, MO; 6Thomas Jefferson University, Philadelphia, PA; 7University of Pennsylvania School of Medicine, Philadelphia, PA; 8Texas Liver Institute, San Antonio, TX; 9Mount Sinai Hospital, New York, NY; 10NYU School of Medicine, New York, NY; 11University of Michigan, Ann Arbor, MI; 12University of Miami, Coral Gables, FL; 13University of North Carolina at Chapel Hill School of Medicine, NC; 14Gilead Sciences, Inc., Foster City, CA; 15Columbia University Medical Center, New
York-Presbyterian, New York, NY; 16Beth Israel Deaconess Medical Center, Boston, MA
|
| |
|
|
|
|
|
